Results 261 to 270 of about 1,499,825 (316)

SuFEx‐Enabled Reprogramming of Flavonoids for Selective α‐Glucosidase Covalent Inhibition

Advanced Science, EarlyView.
Selective inhibition of intestinal α‐glucosidase remains limited by poor enzyme specificity and off‐target metabolic effects. Here, SuFEx click chemistry is used to reprogram natural flavonoids into covalent inhibitors with enhanced α‐glucosidase selectivity and controlled reactivity. This strategy enables effective regulation of carbohydrate digestion
Fengyu Guo, Liwei Zhang, Minlong Wang, Yanjin Du, Tianyu Zhang, Hao Chen, Jiazeng Sun, Yang Yu, Zude He, Jie An, Xiaoxu Zhang, Weilin Lin, Fazheng Ren, Pengjie Wang, Ping Liu   +14 more
wiley   +1 more source

Correction: Development and recalibration of a multivariable type 1 diabetes prediction model for type 1 diabetes across multiple screening studies. [PDF]

BMC Med
Templeman EL, Ferrat LA, Parikh HM, You L, Triolo TM, Steck AK, Hagopian WA, Vehik K, Onengut-Gumuscu S, Gottlieb PA, Rich SS, Krischer JP, Redondo MJ, Oram RA, Type 1 diabetes TrialNet Study Group.   +14 more
europepmc   +1 more source

ApoA1 and ApoB Are Associated with Fracture Risk in Patients with Type 1 Diabetes. [PDF]

J Clin Med
Paulsson E, Catrina SB, Toppe C, van Asseldonk E, Arnqvist HJ, Chisalita SI.   +5 more
europepmc   +1 more source

Multimorbidity and the Number of Conditions Increase With the Duration of Type 1 Diabetes and Associate With Increased Mortality. [PDF]

J Diabetes
Ylinen A, Mutter S, Hägg-Holmberg S, Satuli-Autere S, Harjutsalo V, Groop PH, Thorn LM, FinnDiane Study Group.   +7 more
europepmc   +1 more source

Life stage transitions for people with type 1 diabetes. [PDF]

Lancet Diabetes Endocrinol
Vitale RJ, Toschi E, Ortega J, Munshi MN, Weinstock RS, Laffel LM, Kahkoska AR.   +6 more
europepmc   +1 more source

Preschool and primary school teachers' attitudes toward students with type 1 diabetes: A cross-sectional study. [PDF]

PLoS One
Martín-Báez MY, Díaz-González CM.
europepmc   +1 more source

Emerging therapies for type 1 diabetes: Immunotherapy and gene editing advances. [PDF]

J Int Med Res
Zhao M, Yao Z.
europepmc   +1 more source